1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus Erythematosus

29 Jan 2026
Admin
News Article

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus Erythematosus

The Lupus Research Alliance has welcomed the US Food and Drug Administration’s (FDA) decision to grant Breakthrough Therapy designation to litifilimab (BIIB059), an investigational therapy from Biogen, for the treatment of cutaneous lupus erythematosus (CLE).

CLE is a chronic skin disease and one of the most common manifestations of lupus. Currently, there are no specifically approved treatments for this condition.

The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of drugs that may offer substantial improvement over existing therapies.

Why this designation matters for CLE patients?

CLE primarily causes inflammation of the skin and can present with a wide range of symptoms, including:

Butterfly-shaped facial rashes
Ring-shaped lesions
Red, scaly skin patches

Over time, CLE may lead to:

Irreversible scarring
Changes in skin pigmentation
Hair loss

These effects can significantly reduce a patient’s quality of life.

CLE symptoms affect an estimated 70–85% of people with lupus, underscoring the urgent need for targeted therapies.

Litifilimab targets a key lupus disease pathway

Litifilimab is a humanized IgG1 monoclonal antibody that targets BDCA2, a molecule involved in the activation of plasmacytoid dendritic cells and the production of type I interferons.

Type I interferons are known to play a central role in lupus-related inflammation.

According to Biogen, the Breakthrough Therapy designation was supported by data from the Phase 2 LILAC study. Litifilimab is now being evaluated in the ongoing Phase 3 AMETHYST trial.

Longstanding collaboration between Lupus Research Alliance and Biogen

The Lupus Research Alliance has partnered with Biogen for many years to advance lupus drug development.

Key areas of collaboration include:

Lupus Therapeutics, the Alliance’s clinical affiliate, supporting Phase 2 and Phase 3 trials
Ensuring patient perspectives are incorporated into study design
Trial leadership by members of the Lupus Clinical Investigators Network (LuCIN)

Biogen is also a member of the Lupus Accelerating Breakthroughs Consortium (Lupus ABC), a public-private partnership with the FDA focused on speeding the development of safer and more effective lupus treatments. The consortium includes a dedicated working group for CLE.

About lupus

Lupus is a chronic autoimmune disease in which the immune system attacks the body’s own tissues.

It can affect organs and systems including:

Skin
Kidneys
Brain
Heart
Lungs
Blood and joints

Approximately 90% of people with lupus are women, most often diagnosed between ages 15 and 45. Certain populations, including Black, Latinx, Indigenous, Asian, and Pacific Islander communities, are disproportionately affected.